10:39 AM Jul 20th
• BOSTON (Reuters) - Human Genome Sciences Inc said on Monday that its experimental lupus drug had succeeded in a late-stage clinical trial, shocking many who had written the product off and fueling a 195 percent jump in the company's stock. …
full story